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are associated with presence of a CpG island methylator phenotype 
(CIMP), codeletions of the chromosomal arms 1p and 19q (1p/19q), 
and epigenetic silencing of the O6-methylguanine-DNA methyl-
transferase (MGMT) gene that are determined routinely in many brain 
tumor centers due to their diagnostic, prognostic, or predictive value.  
MGMT is frequently silenced by promoter methylation and was found 
to be predictive in glioblastoma for benefit from the addition of the 
alkylating agent therapy temozolomide to radiotherapy, the current 
standard of care. A predictive value was recently confirmed in two 
trials treating elderly glioblastoma patients with either temozolomide 
or radiotherapy. This had a practice changing impact and requires now 
MGMT testing for treatment decision. However, in anaplastic glioma 
MGMT methylation has been reported from two clinical trials to be 
only prognostic. This puzzling result suggested that the molecular 
context of MGMT methylation may be different between these glioma 
subtypes. Indeed, the genetic and epigenetic context is strikingly 
different. In glioblastoma loss of one copy of chromosome 10 on which 
MGMT resides (CHR 10q23) is very frequent (>80%) as opposed to 
anaplastic glioma. Interestingly, in low grade and anaplastic glioma 
MGMT mutations are highly associated with CIMP. Mutations in IDH 
have been found to be an early event, very common in low grade and 
anaplastic glioma (50-80%), while they are infrequent in glioblastoma 
(<10%), usually associated with secondary glioblastoma that evolve 
through evolution of lower grade precursor lesions. Recent 
publications provided evidence that IDH1/2 mutations indirectly, 
through production of an onco-metabolite lead to epigenetic 
deregulation resulting in CIMP. Hence the epigenetic and genetic 
context of MGMT methylation in glioblastoma is different from 
anaplastic glioma. Emphasizing that IDH mutant/CIMP positive gliomas 
are patho-genetically distinct entities with different biological and 
clinical features that respond differently to treatment approaches. 
These insights need to be taken into consideration for future trial 
design.Co-deletions of 1p/19q are usually associated with IDH 
mutations, hence oligodendroglial tumors seem to be a favorable 
subgroup of CIMP associated glioma. Retrospective analysis of two 
clinical trials for anaplastic glioma suggested that 1p/19q co-deletions 
are predictive for benefit from the early addition of chemotherapy to 
radiotherapy a practice changing finding. 
Among the many signatures and molecular markers identified in 
glioma actionable markers are, unfortunately, rare with the currently 
available treatments. New strategies have to be adopted to test 
promising drugs in molecularly stratified patient populations.  
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Current goals of drug design in oncology are to discover and target 
therapies to specific receptors or antigens on tumors, while 
simultaneously avoiding systemic toxicity. Even the targeted therapies 
on the market have notable systemic toxicities, as many of the targets 
are not unique to tumors. Solid tumors contain a unique micro-
environment that is often not conducive to drug distribution. Drugs 
often reach tumor sites by penetrating across the endothelial linings 
of the capillaries, but different pressure gradients inside the tumor 
influence the ability of drugs to extravasate.  
One of the unique aspects of using X-ray radiation therapy (XRT) for 
treating tumors is that it can be delivered to a focused tissue volume. 
This allows for the deposition of high cumulative radiation doses at 
the tumor site while sparing the normal surrounding tissues. New 
research done in the last decade has shown that XRT, although also 
therapeutic, can induce neoantigens at the cell surface of tumors and 
tumor blood vessels. The usefulness of neoantigens for therapeutic 
applications lies in the fact that they are differentially expressed on 
the surface of irradiated tumor cells to a greater extent than on 
normal tissues. This differential expression provides a mechanism by 
which tumor cells can be “marked” by radiation for further targeting. 
Using phage display biopanning, recombinant peptides that bind 
preferentially to radiation-treated cancers have been found. Drug 
delivery vehicles conjugated to ligands that recognize and interact 
with the neoantigens can help to improve tumor-specific targeting and 
potentially reduce systemic toxicity with cancer drugs.  
For instance, our group has found that glucose regulated protein 78 
(GRP78) is present in low levels in normal tissue, shows increased 
expression in numerous solid tumors, and is upregulated after 
treatment with XRT, providing a tumor-specific target for drug 
delivery. The targeting peptide specifically binds to GRP78 post-XRT 
and not normal tissue which allows for an increased percentage of 
drug load to be directly delivered to the radiation-treated tumor 
volume. By using radiation treatment as a means to “mark” the tumor 
for drug delivery, this new potential form of treatment hopes to 
dramatically reduce the systemic toxicity that is typically associated 
with cancer drugs, while simultaneously increasing the biodistribution 
of these drugs to the tumor region. 
In addition to active targeting, alternative methods for tumor-toxic 
payloads have been created, which capitalize on radiation-induced 
targets. XRT has been shown to improve the delivery of nanoparticles 
to tumor cells because it transiently increases the permeability and 
retention effect of the vasculature after single treatments at 
clinically-relevant doses. Another strategy is the use of adenoviruses 
whose transfection rates increase in the presence of ionizing 
radiation. This same technology has led to the creation of the product 
TNFerade, in which TNF-alpha is produced by a radiation-inducible 
promoter but predominantly within the radiation field. This product 
has been successfully tested in phase III clinical trials. 
The characteristics of ionizing radiation that make it an appealing 
option targeting nanoparticles are multiple. First, it is already 
ubiquitously used in cancer treatment protocols. Second, when used 
at low doses for short periods of time, radiation therapy is associated 
with relatively few side effects. Third, it readily penetrates tissue. 
Fourth, it can be accurately delivered to specific tumor volumes while 
sparing surrounding normal tissues. Fifth, it induces site-specific gene 
transcription and protein expression within cancer. Finally, tumor 
targeting peptides are being discovered that bind to radiation-
inducible receptors; these peptides can be functionalized with 
nanoparticle carriers to enable radiation-guided delivery of 
chemotherapy to the tumor microvasculature. Further research 
exploring these targets for therapeutic purposes as well as in the 
discovery of novel radiation-induced antigens will aid in improving 
targeted strategies and the efficacy of radiotherapy. 
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Image guided drug delivery requires physical energy that is deposited 
within cancer to activate drug delivery. The classic example is boron 
neutron capture. More recently, heat has been used to “melt” 
liposomes for thermal control of drug delivery. Ionizing radiation is 
also used to induce the expression of receptors and antigens for 
targeted drug delivery. Magnetic fields are used to guide drug delivery 
and oscillate magnetic nanoparticles to heat tumors. Radiation 
oncologists are uniquely trained in the field of image guided delivery 
of therapy. ESTRO and ASTRO should develop each of these forms of 
external administration of energy to control drug delivery. Although 
these strategies are complementary, they vary in their feasibility to 
bring drug delivery systems into clinical trials and in their cancer 
specificity. Each strategy has its limitations. For example, radiation 
inducible neoantigens and receptors are not induced in every cancer 
subtype. Magnetic fields are site specific but not cancer specific 
which could lead to drug delivery throughout the entire magnetic 
field. Similarly, heat is site specific but not cancer specific and could 
result in drug delivery to adjacent normal tissues. Moreover, the 
thermal regulated liposomes can release the drug systemically. 
Pharmacokinetics of each of these forms of image guided drug 
delivery vary. For example, thermal regulated drug delivery produces 
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rapid release of the drug whereas other modalities can have sustained 
drug delivery. The speakers in this forum will describe the pros and 
cons of each of the drug delivery systems that are designed to 
improve bioavailability of cancer chemotherapy to sites of neoplasia. 
X-ray guided drug delivery exploits the stress response within cancer 
that occurs during radiotherapy. Low doses of radiation induce DNA 
strand breaks and oxidative stress within cancer. Stress proteins such 
as GRP78, TIP1 and Calreticulin are induced and transported to the 
surface of cancer cells following irradiation. Antibodies and peptide 
ligands that are specific to these radiation inducible neoantigens are 
used to coat the surface of nanoparticles and liposomes for guided 
drug delivery. This strategy of x-ray guided drug delivery is analogous 
to military use of lasers to tag targets for smart bombs. X-rays are 
tissue penetrating and therefore tag deep seated cancers for the 
binding of antibodies and peptide ligands. The discovery platform for 
this technology identifies inducible antigens that are specific to 
cancer and not induced in normal tissues. Antigens that are induced in 
normal tissues are discarded while cancer specific antigens are 
developed. These targeting moieties are conjugated to drug delivery 
systems. In contrast, hyperthermia is used to heat a tumor. As 
liposomes pass through the tumors, the lipids melt and release the 
drug in that volume. This strategy of thermal regulation of drug 
delivery has entered Phase III clinical trials in breast cancer to deliver 
Doxorubicin. The use of magnetic nanoparticles for drug delivery is 
still in the preclinical stage. Paramagnetic nanoparticles have been 
targeted to tumors for both drug delivery and to heat tumors. 
Oscillating magnetic fields cause these nanoparticles to vibrate and 
heat the tumor to induce hyperthermia. These three forms of image 
guided drug delivery will becompared and contrasted during the 
debate of the practicality of bringing these new strategies of drug 
delivery into clinical trials.  
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Proton beam therapy seems to offer significant advantages over 
conventional techniques especially for the pediatric cohort and the 
number of children being treated with proton therapy for solid tumors 
is increasing rapidly throughout the world. There have been multiple 
dosimetric studies clearly demonstrating that protons decrease the 
irradiated volume and therefore the dose to the developing normal 
tissues compared with photon techniques while showing excellent 
outcome in the pediatric population. As in paediatric malignancies 
survival rates have increased considerably, from 0-20% until the 50ies 
up to about 80% today, quality of life (QoL) and late sequelae have 
become a major concern in pediatric cancer survivors. Therefore, 
proton therapy was understood as a tool potentially reducing the risk 
for secondary malignancy induction as well as for late effects. As 
children are particularly sensitive to radiation injury, they seem to be 
the cohort taking the greatest potential benefit from sparing dose to 
normal tissue. Today, local treatment with proton beam in CNS 
tumors or sarcomas is a common choice to be offered to the pediatric 
cohort in Europe and in US whenever available. 
It is suggested from early reports, that secondary cancer incidence 
may be reduced by 50% when using proton therapy. Additional early 
data was published on neurocognitive functioning and quality of life, 
both suggesting favourable outcome after proton beam therapy. Still, 
prospective data are limited, cohorts are small and observation times 
not sufficient, especially when looking at very young children being 
treated with proton beam therapy. 
In conclusion, proton beam therapy is a promising tool to explore 
particularly in the pediatric cohort to reduce the risk for late effects 
and secondary malignancies; however, due to limited availability up 
to now, clinical experience of proton therapy in childhood cancer is 
still limited. Therefore, all pediatric programs should be accompanied 
by prospective evaluations of late effects and QoL to gather more 
information on optimal use of proton therapy. Due to small number of 
patients and ethical considerations, randomized data will be hardly 
available even on the long term in children. Still, more clinical data 
will be emerging to quantify the clinical benefit of proton beam 
therapy with regard to a decrease in late effects while maintaining 
excellent cancer control rates.  
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Purpose/Objective: The aim of this study is to investigate the 
predictive value of the modelled tumour control probability (TCP) 
based on BED calculations using individual measurements of in vitro 
radiosensitivity (SF2) and potential doubling time (Tpot) for head and 
neck (H&N) cancer patients versus literature-based average 
radiobiological parameters. 
Materials and Methods: Tumour radiosensitivity, measured in vitro on 
primary biopsies and expressed as surviving fraction of cells following 
an acute exposure of 2 Gy (SF2), Tpot and tumour size were determined 
for 46 H&N cancer patients. All patients were treated with external 
beam radiotherapy and 28 patients also received brachytherapy. For 
each patient TCP was calculated using a Poisson-LQ model based 
either on the patient-specific radiobiological parameters or literature-
based average radiobiological parameters (α=0.3 Gy-1 and Tpot=3 days). 
The predicted TCP values for the two sets of parameters were 
compared with the actual outcome for the patients in terms of local 
control. 
Results: The average radiobiological parameters lead to a large 
underestimationof TCP as the predicted TCP was below 10% for the 
majority of the patients that actually presented local control. When 
tumour specific parameters were used,the majority of the patients 
with local control had a predicted TCP larger than 90%. 
A Receiver Operating Characteristic (ROC) curve analysis was also 
performed for assessing the predictive values of the two methods for 
calculating the TCP. The corresponding ROC curves are shown in 
Figure 1. 
